Key facts
| Price (PPV) | 29,450 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | axitinib |
| Class | Antineoplastic agents |
| ATC code | L01XE17 |
| Manufacturer | PFIZER MAROC |
| Presentation | Boite de 56 |
| Nature | Médicament |
| Hospital price | 28,880 MAD |
| Data collected on | 9/8/2026 |
Indications
Inlyta est indiqué pour le traitement de patients atteints d’un carcinome rénal avancé (RCC) après échec d’un traitement systémique préalable.
Find an open pharmacy
On-call pharmacies near you
About Inlyta 5 mg
Inlyta 5 mg belongs to the antineoplastic agents therapeutic class. In Morocco, this drug is marketed by PFIZER MAROC and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Inlyta 5 mg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Inlyta 5 mg
Answers to common questions from Moroccan patients about this drug.